Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...

Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity market.

Despite the largest U.S. pharmacy benefit manager (PBM) knocking Zepbound off its formulary this summer, sales of Lilly’s dual-action obesity med continue to impress, thanks in no small part to the ...

A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly’s blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit manager ...

Zepbound and Wegovy treat weight loss and weight management in adults with obesity or overweight. Both drugs are also approved to treat other conditions. These drugs are given as weekly injections, ...